Loading…
← CockpitCompetitor Analysis › SRPT Sarepta Therapeutics, Inc.Open in the cockpit ↗

Sarepta Therapeutics, Inc.SRPTCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Makes exon-skipping drugs and Elevidys gene therapy for Duchenne muscular dystrophy, a rare genetic disease.

Momentum weak 22
Mkt cap
$1.56B
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$31.1M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-7.0 pp
WACC 6.6%
Hurdle
-39 pp
Req g minus delivered
Next earnings
105 days
3 Mar 2027
Close · USD$14.53
1D-1.6%
1W-12.9%
1M-24.2%
3M-24.4%
6M-15.1%
YTD-32.5%
1Y-17.2%
ATR %6.1%
Beta1.75
52w lowhigh41.1% off high

What Sarepta Therapeutics does

Makes exon-skipping drugs and Elevidys gene therapy for Duchenne muscular dystrophy, a rare genetic disease.

Earns from selling a handful of Duchenne drugs, mostly in the US to patients who need them for life. The older exon-skipping injections give steady sales, while Elevidys, a one-time gene therapy, is lumpier. Roche holds rights to market Elevidys outside the US.

Products and services

  • Elevidys (gene therapy)
  • Exondys 51/Vyondys 53/Amondys 45 (exon-skipping)
  • LGMD gene-therapy pipeline

Customers

  • Pediatric neurologists
  • DMD patient families

Where it sits in the supply chain

  • Rare-disease biopharma
  • RNA/exon-skipping and gene-therapy…
  • Duchenne muscular dystrophy treatment

What could go right

  • Elevidys global launch expansion
  • Label broadening to more DMD patients

What could go wrong

  • Gene-therapy safety signals (past patient deaths)
  • Pricing/reimbursement scrutiny

Moat: narrow (IP / patents, regulatory licence). First approved DMD gene therapy and multiple exon-skipping exclusivities are hard to replicate quickly.

Headquarters: Cambridge, Massachusetts, US · Founded: 1980 · Employees: 835

Named competitors

Sarepta Therapeutics at a glance

Size Sarepta Therapeutics (SRPT) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.56B, the 1950th largest of 3,085 United States companies the cockpit tracks. Shares closed at $14.53 on 18 Nov 2026.

Performance Over six months the shares fell 15.1%, against -7.7% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 20 in its peer set.

Growth Revenue fell 18.9% over the last twelve months (peer median +6.8%); the operating margin is -0.4% (peer median 12.0%).

Valuation It trades at 0.9× enterprise value to sales against a peer median of 4.5× (cheapest of 20).

Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +32%, so the hurdle is -39 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 7.0 points below its cost of capital (6.6% WACC).

Credit Sarepta Therapeutics has 2 bonds outstanding ($1.03B).

Short interest Short interest is 18.0% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026Peer median 92SRPT 86
Six months, rebased to 100: Sarepta Therapeutics against the median of its 20 peers (local-currency closes).

Sarepta Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.96B$2.20B$1.90B$1.24B$933M
Revenue growth—+16%+53%+33%—
Gross profit$1.07B$1.31B$1.55B$1.05B$751M
EBITDA$40.9M-$599M$272M-$209M-$476M
Net income-$115M-$713M$235M-$536M-$703M
Free cash flow$172M-$325M-$343M-$577M-$356M
Capital expenditure$13.5M$110M$147M$87.3M$30.8M
Total debt$1.05B$1.04B$1.34B$1.40B$1.62B

Quarterly statements and history in the cockpit →

Sarepta Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-75%-50%-25%0%+25%-20%0%+20%002019002675JUBLPHARMA600572600420002755301047603235ANURAS298380ASTRAZEN000766141080CORONA1681300357002626PAHCINDGNSRPT6-month return →1-month return →
Up and to the right = strong over both horizons. Sarepta Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

-50%-25%0%+25%0×20×40×002019002675JUBLPHARMA600572600420301047603235ANURAS298380ASTRAZEN000766141080CORONA300357INDGNSRPTRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sarepta Therapeutics is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%002675600572600420002755301047603235ASTRAZEN000766CORONA1681300357PAHCINDGNSRPTGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sarepta Therapeutics is the large dot.

Sarepta Therapeutics competitors and peer comparison

Head to head with its named competitors (SRPT vs PFE vs SLDB vs PTCT)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Sarepta Therapeutics SRPT$1.56B-15%-19%0%0.9×-6.8%
Pfizer PFE$160B+9%+1%26%3.3×-4.3%
Solid Biosciences SLDB$709M-2%n/an/an/an/a
PTC Therapeutics PTCT$5.03B-15%-35%22%3.1×6.6%

How Sarepta Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sarepta Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureSRPTPeer medianRank in peer set
1-month return-24.2%-4.6%lowest of 21
6-month return-15.1%-7.7%7th lowest of 20
Distance from 52-week high-41.1%-32.4%7th lowest of 21
Revenue growth (TTM)-18.9%+6.8%3rd lowest of 20
Operating margin-0.4%12.0%3rd lowest of 20
EV / Sales0.9×4.5×cheapest of 20
Growth the price implies (Req g, 7 yrs)-6.8%12.8%2nd least demanding of 14
Growth delivered (Del g)+32.4%+1.9%highest of 14
Hurdle (Req g minus delivered)-39.2 pp+7.6 ppleast demanding of 14
ROIC minus cost of capital-7.0 pp+1.2 pp6th lowest of 21
Net debt / EBITDA4.3×0.1×most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Sarepta Therapeutics SRPTUnited States$1.56B-15%-19%0%0.9×-6.8%+32.4%
Yifan Pharmaceutical 002019.SZChina$1.57B-19%-5%8%2.5×n/an/a
Yantai Dongcheng Biochemicals 002675.SZChina$1.59B0%-4%15%4.5×6.0%-4.3%
Jubilant Pharmova JUBLPHARMA.NSIndia$1.59B-8%+18%7%2.0×n/an/a
Zhejiang CONBA Pharmaceutical 600572.SSChina$1.52B-4%+4%9%1.4×-6.1%+1.9%
Shanghai Shyndec Pharmaceutical 600420.SSChina$1.59B-14%-13%6%1.2×-6.6%-5.6%
Beijing Aosaikang Pharmaceutical 002755.SZChina$1.60B-31%-13%12%5.2×12.8%-14.0%
Sino Biological 301047.SZChina$1.60B+27%+20%17%9.8×31.1%-15.1%
JiangXi Tianxin Pharmaceutical 603235.SSChina$1.52B-9%+16%24%3.5×-4.9%+0.2%
Anupam Rasayan India ANURAS.NSIndia$1.61B-3%+24%16%7.2×n/an/a
ABL Bio 298380.KSSouth Korea$1.51B-71%-53%-201%46.5×n/an/a
AstraZeneca Pharma India ASTRAZEN.NSIndia$1.62B-30%+30%10%5.6×42.4%+23.0%
Tonghua Golden-Horse Pharmaceutical Industry 000766.SZChina$1.62B-47%-18%9%12.2×33.0%+0.9%
LigaChem Biosciences 141080.KSSouth Korea$1.48B-72%-55%-324%17.0×n/an/a
Corona Remedies CORONA.NSIndia$1.48B+27%+17%18%8.9×36.3%+16.6%
Consun Pharmaceutical 1681.HKHong Kong$1.65B+8%+15%35%2.2×-14.9%+13.5%
Braveheart Bio BRVEUnited States$1.67Bn/an/an/an/an/an/a
Zhejiang Wolwo Bio-Pharmaceutical 300357.SZChina$1.67B-12%+7%39%8.9×18.4%+10.8%
Xiamen Kingdomway 002626.SZChina$1.45B-3%-3%11%3.1×n/an/a
Phibro Animal Health PAHCUnited States$1.44B+5%+10%13%1.4×-6.4%+12.7%
Indegene INDGN.NSIndia$1.69B+28%+36%12%3.6×31.4%+29.4%

Sarepta Therapeutics bonds and credit

Sarepta Therapeutics has 2 bonds outstanding with $1.03B face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Sarepta Therapeutics's main competitors?
Named competitors: Pfizer (DMD gene therapy, discontinued) (PFE), Solid Biosciences (SLDB), PTC Therapeutics (PTCT). The cockpit's measured peer set (industry) also includes Yifan Pharmaceutical (002019.SZ), Yantai Dongcheng Biochemicals (002675.SZ), Jubilant Pharmova (JUBLPHARMA.NS), Zhejiang CONBA Pharmaceutical (600572.SS), Shanghai Shyndec Pharmaceutical (600420.SS), Beijing Aosaikang Pharmaceutical (002755.SZ).
Is Sarepta Therapeutics expensive compared with its peers?
On ev / sales it trades at 0.9× against a peer median of 4.5×, cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +32%, so the hurdle is -39 pp: the price already allows for a slowdown.
How has Sarepta Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -15.1% against -7.7% for the median peer; over one year -17.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.